Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Brain Connectivity in Depression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03276793
Recruitment Status : Recruiting
First Posted : September 8, 2017
Last Update Posted : May 18, 2022
Butler Hospital
Information provided by (Responsible Party):
Michael D. Fox, M.D.,Ph.D., Brigham and Women's Hospital

Brief Summary:
This study will include 60 subjects with medication-refractory depression undergoing transcranial magnetic stimulation (TMS) to the left dorsal lateral prefrontal cortex (DLPFC). In order to obtain good quality data and account for attrition, 100 subjects will be recruited. Subjects will be recruited from the Clinical Program of FDA approved TMS at the Center for Brain Circuit Therapeutics TMS Clinic and the Butler TMS Clinic. Subjects will undergo an hour-long MRI scanning session, an optional DNA-sample collection, up to three 20 minute neuronavigation sessions for marking the site of TMS stimulation, questionnaires, and a behavioral testing battery before and after their TMS treatment course. The task battery will last 45-60 minutes and consist of the Emotion Conflict Resolution (ECR) task, Multi-Source Interference Task (MSIT), War Game (Gambling) task, and Associative Learning with Reversal task. Subjects' scores on the Quick Inventory of Depressive Symptomatology (QIDS) and Beck Depression Inventory (BDI) will also be assessed before and after the TMS course. MRI data will be utilized to identify brain regions whose connectivity to the stimulation site co-varies with the aforementioned objective measures of symptom improvement.

Condition or disease Intervention/treatment Phase
Depression Other: MRI scan Behavioral: Behavioral testing Not Applicable

Detailed Description:
This study was originally approved by the Beth Israel Deaconess Medical Center (BIDMC) Institutional Review Board (IRB) with Butler Hospital as a relying site. The study is now transferred to the Mass General Brigham (MGB) IRB so that Dr. Fox, as the lead PI, can continue to provide oversight as his primary appointment is now at Brigham and Women's Hospital (BWH). Butler Hospital is now relying on the MGB IRB for regulatory oversight and will also be conducting all study procedures, while BIDMC will not become a relying site and will stop enrolling subjects. A Data Usage Agreement is established between BIDMC and BWH, and all previously collected Data will be de-identified and sent to BWH. The protocol at BIDMC will remain active but not enrolling until all the de-identified data has been sent to BWH.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Using Human Brain Connectivity to Identify the Causal Neuroanatomical Substrate of Depression Symptoms
Actual Study Start Date : April 3, 2018
Estimated Primary Completion Date : October 31, 2022
Estimated Study Completion Date : October 31, 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: MRI and behavioral assessment
Subjects will undergo an hour-long MRI scanning session, a marking for the site of planned clinical TMS stimulation and a behavioral testing battery before and after their TMS treatment course.
Other: MRI scan
Patients will undergo an MRI scan

Behavioral: Behavioral testing
Patients will complete a series of cognitive tasks

Primary Outcome Measures :
  1. Prediction of repetitive Transcranial Magnetic Stimulation (rTMS) clinical response [ Time Frame: 1 year after study completion ]
    Connectivity between each patient's stimulation site and the subgenual cingulate will be used to predict clinical response to rTMS

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female
  2. Aged 18-70.
  3. Have previously received or will receive TMS to the left dorsal-lateral prefrontal cortex as part of the clinical treatment program at the Center for Brain Circuit Therapeutics at Brigham and Women's Hospital, or at Butler Hospital for treatment of medication resistant depression

Exclusion Criteria:

  1. Any current or past history of a major psychiatric illness other than depression and anxiety (e.g. bipolar affective disorder, schizophrenia, obsessive compulsive disorder, post-traumatic stress disorder, generalized anxiety disorder)
  2. Any significant current neurological illness (e.g. a history of seizures or unexplained loss of consciousness, a family history of epilepsy, signs of increased intracranial pressure, previously abnormal MRI scans, parkinsonism or dementia). Of note, most of these are also contraindications to receiving TMS and these patients would not be enrolled in the clinical treatment program.
  3. Patients who are pregnant or lactating (by menstrual history)
  4. Current abuse of an illicit substance (e.g. marijuana, cocaine, heroin, hallucinogens, psychostimulants)
  5. Positive MRI screen that would preclude the subject from undergoing magnetic resonance imaging. These include, but are not limited to any of the following:

    1. Known metal in the head (such as a surgical aneurysm clip), or a history of prior neurosurgical procedures
    2. Ferromagnetic bioimplants activated by any electronic, mechanical or magnetic means such as: cochlear implants, pacemakers, medication pumps, vagal stimulators, deep brain stimulators, neurostimulators, biostimulators, or ventriculo-peritoneal shunts
    3. Subjects who have or might have bullet fragments or other metal fragments (veterans or workers exposed to metal in their work environment)
    4. Subjects with metallic paint (e.g. color contact lenses, tattoos, metallic eyeliner)
    5. Subjects expressing significant anxiety or claustrophobia about being in the magnet.
  6. Subjects that cannot adhere to the experimental protocol for any reason.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03276793

Layout table for location contacts
Contact: Stephan Palm, BS 617-732-6658
Contact: Christopher Lin, BS

Layout table for location information
United States, Massachusetts
Brigham and Women's Hospital Recruiting
Boston, Massachusetts, United States, 02115
Contact: Michael D Fox, MD, PhD    617-732-7432   
Sub-Investigator: Sandrine Jabbour, BS         
Principal Investigator: Michael D Fox, MD, PhD         
Sub-Investigator: Joseph J Taylor, MD, PhD         
Sub-Investigator: Claudia Becker, BS         
Sub-Investigator: Jing Li, BS         
Sub-Investigator: Christopher Lin, BS         
Beth Israel Deaconess Medical Center Active, not recruiting
Boston, Massachusetts, United States, 02215
United States, Rhode Island
Butler Hospital Recruiting
Providence, Rhode Island, United States, 02906
Contact: Linda Carpenter, MD    401-455-6632   
Sub-Investigator: Eric Tirrell, BS         
Sponsors and Collaborators
Brigham and Women's Hospital
Butler Hospital
Layout table for additonal information
Responsible Party: Michael D. Fox, M.D.,Ph.D., Associate Professor, Brigham and Women's Hospital Identifier: NCT03276793    
Other Study ID Numbers: 2021P000335
First Posted: September 8, 2017    Key Record Dates
Last Update Posted: May 18, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders